| P50 | author | Maura Dowling | Q38589649 |
| P2093 | author name string | Mary Kelly | |
| | Teresa Meenaghan | |
| P2860 | cites work | Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma | Q28266655 |
| | Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials | Q28275006 |
| | Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma | Q33405119 |
| | Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma | Q33423168 |
| | Destined to die in hospital? Systematic review and meta-analysis of place of death in haematological malignancy | Q33591670 |
| | Older adults newly diagnosed with symptomatic myeloma and treatment decision making | Q33820143 |
| | Maintaining bone health in patients with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. | Q34307388 |
| | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma | Q34450381 |
| | Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients | Q34798105 |
| | Fatigue, sleep, pain, mood, and performance status in patients with multiple myeloma | Q34905283 |
| | Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report | Q35220639 |
| | European Myeloma Network guidelines for the management of multiple myeloma-related complications | Q36115636 |
| | Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. | Q36209159 |
| | Myeloma today: Disease definitions and treatment advances | Q36470699 |
| | Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group | Q36839385 |
| | Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy | Q37280739 |
| | Health related quality of life in a nationally representative sample of haematological patients | Q37314857 |
| | Treatment of multiple myeloma: a comprehensive review | Q37542173 |
| | Bisphosphonate-related osteonecrosis of the jaw in cancer patients: Implications for nurses | Q37686874 |
| | Guidelines for supportive care in multiple myeloma 2011. | Q37868637 |
| | Guidelines for the diagnosis and management of multiple myeloma 2011. | Q37875193 |
| | Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). | Q37917337 |
| | Genetic variations in multiple myeloma I: effect on risk of multiple myeloma | Q37924891 |
| | Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor | Q38118900 |
| | Second autologous transplant as salvage therapy in multiple myeloma | Q38151157 |
| | Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review. | Q38170525 |
| | Therapy-related peripheral neuropathy in multiple myeloma patients. | Q38268525 |
| | Treatment-related symptom management in patients with multiple myeloma: a review | Q38342281 |
| | Treatment options for relapsed and refractory multiple myeloma | Q38403304 |
| | Frontline therapy of multiple myeloma. | Q38403316 |
| | Managing relapsed myeloma: The views of patients, nurses and doctors | Q38559553 |
| | Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma | Q38716460 |
| | Ixazomib: First Global Approval | Q38723292 |
| | Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners | Q39897149 |
| | Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy | Q40150284 |
| | Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital | Q41610012 |
| | Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma | Q41662704 |
| | Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma | Q41700620 |
| | Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma. | Q42384494 |
| | Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. | Q42573839 |
| | Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo | Q42592824 |
| | An exploration of the lived experiences of individuals with relapsed multiple myeloma. | Q42678687 |
| | Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents | Q43050995 |
| | Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial | Q43700291 |
| | End-of-life care in hematology: update from Australia | Q44110952 |
| | Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management | Q44977303 |
| | Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. | Q45250187 |
| | A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors | Q45716342 |
| | Exercise compliance among patients with multiple myeloma undergoing chemotherapy: a retrospective study | Q47571717 |
| | The work of living with a rare cancer: multiple myeloma. | Q47890138 |
| | Early application of percutaneous vertebroplasty reduces pain without affecting peripheral blood stem cell (PBSC) collection and transplant in newly diagnosed multiple myeloma (MM) patients | Q48126547 |
| | Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. | Q53362023 |
| | Genetic variation at the 8q24 locus confers risk to multiple myeloma | Q57515011 |
| | Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma | Q57903998 |
| | Redefining myeloma | Q58030074 |
| | Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma | Q58050813 |
| | Updates to the guidelines for the diagnosis and management of multiple myeloma | Q58417652 |
| | Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results | Q58417653 |
| P433 | issue | 16 | |
| P921 | main subject | multiple myeloma | Q467635 |
| P304 | page(s) | S18-28 | |
| P577 | publication date | 2016-09-01 | |
| P1433 | published in | British Journal of Nursing | Q15754463 |
| P1476 | title | Multiple myeloma: managing a complex blood cancer | |
| P478 | volume | 25 | |